Pale Fire Capital SE Boosts Stake in Aquestive Therapeutics, Inc. $AQST

Key Points

• Pale Fire Capital SE increased its stake in Aquestive Therapeutics by 154.1% during the first quarter, owning 1,335,684 shares, which is now 0.5% of its total investment portfolio.
• Despite a loss per share of ($0.14), Aquestive's revenue for the last quarter was $10 million, slightly below the estimated $11.32 million.
• Research analysts have maintained a consensus rating of "Moderate Buy" for the stock, with several setting target prices including a $10.00 price target from HC Wainwright.

Pale Fire Capital SE increased its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 154.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,335,684 shares of the company's stock after purchasing an additional 809,928 shares during the quarter. Aquestive Therapeutics accounts for 0.5% of Pale Fire Capital SE's investment portfolio, making the stock its 18th biggest holding. Pale Fire Capital SE owned approximately 1.34% of Aquestive Therapeutics worth $3,873,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in AQST. Summit Wealth & Retirement Planning Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth $29,000. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth $31,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth $33,000. Two Sigma Advisers LP acquired a new position in shares of Aquestive Therapeutics in the fourth quarter worth $57,000. Finally, Virtu Financial LLC acquired a new position in shares of Aquestive Therapeutics in the first quarter worth $58,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

AQST stock traded down $0.04 during trading on Friday, reaching $3.80. 431,123 shares of the stock traded hands, compared to its average volume of 1,511,560. The business's 50 day moving average price is $3.85 and its 200-day moving average price is $3.20. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The firm has a market capitalization of $378.44 million, a PE ratio of -5.42 and a beta of 1.99.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Oppenheimer started coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.14.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.